- Home
- » Tags
- » Thiazolidinedione
Top View
- Pioglitazone, a Thiazolidinedione Derivative, Attenuates Left Ventricular Hypertrophy and Fibrosis in Salt-Sensitive Hypertension
- A New Thiazolidinedione, NC-2100, Which Is a Weak PPAR
- Do Thiazolidinediones Cause Heart Failure? a Critical Review
- Thiazolidinedione 2
- Antiretroviral Drug-Induced Endothelial Dysfunction Is Improved by Dual
- The Effect of Antidiabetic Medications on Non-Alcoholic Fatty Liver Disease
- Comparison of Insulin Degludec/Insulin
- Thiazolidinedione Effects on Blood Pressure in Diabetic Patients with Metabolic Syndrome Treated with Glimepiride
- Therapeutic Class Review Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
- Avandia Label
- Dipeptidyl Peptidase-4 Inhibitors Clinical Data and Clinical Implications
- A Promising Mechanism of Action for New Anticancer Drugs?
- The Clinical Role of Insulin Degludec/Insulin Aspart in Type 2 Diabetes: an Empirical Perspective from Experience in Australia
- (DPP-4) Inhibitors Be Avoided in Patients with Heart Failure?
- Thiazolidinediones and the Promise of Insulin Sensitization in Type 2 Diabetes
- Thiazolidinedione Therapy for Managing Metabolic Syndrome MICHAEL D
- Rethinking Pioglitazone As a Cardioprotective Agent
- Insulin Degludec (Tresiba®, Novo Nordisk A/S) for the Treatment of Diabetes: Effectiveness, Value, and Value-Based Price Benchmarks
- Dipeptidyl Peptidase (DPP)-IV Inhibitors with Antioxidant Potential Isolated from Natural Sources: a Novel Approach for the Management of Diabetes
- Improvement of Glycemic Control, Triglycerides, And
- Dementia Diagnosis Is Associated with Changes in Antidiabetic Drug Prescription: an Open-Cohort Study of ∼130,000 Swedish Subjects Over 14 Years
- Avandia, INN-Rosiglitazone
- Pparγ-Independent Side Effects of Thiazolidinediones on Mitochondrial Redox State in Rat Isolated Hearts
- ACTOS™ (Pioglitazone Hydrochloride) Tablets NDA No
- Risk Assessment and Risk Mitigation Review(S)
- Type 2 Diabetes in Real-Life: Population-Based Danish Studies of Incidence, Prognosis, and Treatment Effectiveness
- Ryzodeg, INN-Insulin Degludec/Insulin Aspart
- Thiazolidinediones: the Forgotten Diabetes Medications
- Current and Upcoming Pharmacotherapy for Non-Alcoholic Fatty Liver Disease Yaron Rotman,1 Arun J Sanyal2
- Insulin Degludec Insulin Aspart (Ryzodeg 70 30) Prescribing Protocol.Pdf
- Saroglitazar, a Novel Cardiometabolic Agent for Diabetic Dyslipidemia – a Review
- AVANDIA Safely and Effectively
- Retinoids Augment Thiazolidinedione Pparγ Activation in Oral Cancer
- Drug Class Review on Thiazolidinediones
- Saroglitazar
- The Journey of Thiazolidinediones As Modulators of Ppars for the Management of Diabetes: a Critical Review
- Diabetic Dyslipidemia
- Association Between Thiazolidinedione Treatment and Risk of Macular Edema Among Patients with Type 2 Diabetes